Pulmonary Function Tests and Their Associated Factors Among Type 2 Diabetic Patients at Jimma Medical Center, in 2019; Comparative Cross-Sectional Study
Authors Tesema DG, Gobena T, Ayalew A
Received 13 February 2020
Accepted for publication 18 March 2020
Published 8 April 2020 Volume 2020:13 Pages 111—119
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Dereje Gemeda Tesema,1 Teshome Gobena,2 Almaz Ayalew2
1Mettu University, Faculty of Medical Sciences, Department of Biomedical Sciences, Mettu, Ethiopia; 2Jimma University, Institute of Health, Faculty of Medical Sciences, Department of Biomedical Sciences, Jimma, Ethiopia
Correspondence: Almaz Ayalew
Jimma University, Institute of Health, Faculty of Medical Sciences, Department of Biomedical Sciences, Jimma, Ethiopia
Tel +251 17239525
Background: The presence of widespread lung microvascular circulation and abundant connective tissue with a large reserve raises the possibility that the lung may be a target organ of the pathologic processes induced by type 2 diabetes. Pulmonary function tests (PFTs) are noninvasive medical tests that show how well the lungs are working.
Objective: The aim was to compare pulmonary function tests (PFTs) and their associated factors among type 2 diabetic patients and non-diabetics at Jimma Medical Center (JMC).
Methods: A comparative cross-sectional study was conducted at JMC, Jimma, Southwest Ethiopia among 298 study participants from April 1 to May 30, 2019. A face-to-face interview with semi-structured questionnaire was conducted. Forced vital capacity (FVC), forced expiratory volume in one second (FEV1), ratio of FEV1/FVC, peak expiratory flow (PEF), and forced expiratory flow (FEF25− 75) were recorded by using a digital Spirometer. Independent samples t-test, simple and multiple linear regression analysis were used.
Results: The present study indicated that means of the PFTs among type 2 diabetics were significantly reduced when compared to their matched non-diabetics (FVC (%) (m=73.7± 13.8 vs m=93.8± 12.3), FEV1 (%) (m=76.4± 13.4 vs m=93.3± 12.4), FEV1/FVC (%) (m=78.99± 11.4 vs m=96.6± 9.33), PEF (L/s) (m=3.91± 0.28 vs m=5.03± 0.35), and FEF25– 75 (L/s) (m=2.89± 0.75 vs m=3.39± 0.82)). This study also indicated that body mass index (BMI) (β=− 1.93, P< 0.001) and fasting blood sugar (FBS) (β=− 0.22, P< 0.001) were negative predictors of FVC%. BMI (β=− 1.93, P< 0.001) and FBS (β=− 0.29, P< 0.001) were negative predictors of FEV1%. BMI (β=− 1.403, P< 0.001) was a negative predictor of mean FEV1/FVC. BMI (β=− 1.39 P< 0.001) and FBS (β=− 0.15, P< 0.001) were negative predictors of mean PEF (L/s). BMI (β=− 0.075, P< 0.001) and FBS (β=− 0.075, P< 0.001) were negative predictors of FEF25– 75 (L/s).
Conclusion: The present study showed that there were significantly reduced mean scores of FVC, FEV1, FEV1/FVC, PEF, and FEF25– 75 among type 2 diabetic patients as compared to non-diabetic participants. The FBS and BMI were independent risk factors of the PFTs among the diabetics, unlike among non-diabetic participants.
Keywords: type 2 DM, PFTs, associated factors, Jimma Medical Center
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]